Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial
Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial
复制标题
DOI：
10.1016/s2352-3026(18)30182-0
复制
发表时间：
2019-01-01
影响因子：
24.7
通讯作者：
Ravandi, Farhad
中科院分区：
文献类型：
--
作者：
Short, Nicholas J.;Kantarjian, Hagop M.;Ravandi, Farhad
背景低甲基化药物，如地西他滨，是新诊断的急性髓性白血病老年患者的标准治疗。单组研究表明，地西他滨10天周期方案比通常的5天周期方案结局更好。我们比较了这两种方案的疗效和安全性。方法符合条件的患者年龄为60岁或以上的急性髓系白血病，但不适合强化化疗（或
Background Hypomethylating agents, such as decitabine, are the standard of care for older patients with newly diagnosed acute myeloid leukaemia. Single-arm studies have suggested that a 10-day schedule of decitabine cycles leads to better outcomes than the usual 5-day schedule. We compared the efficacy and safety of these two schedules.Methods Eligible patients were aged 60 years or older with acute myeloid leukaemia but unsuitable for intensive chemotherapy (or